Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/18/2003US20030232092 Liquid antacid compositions
12/18/2003US20030232091 Particles or microspheres of a hydrophobic matrix material having retinol encapsulated therein; sustained release of retinol during the product shelf-life
12/18/2003US20030232090 Anhydrous antifungal gel comprising polyhydric alcohol(s), a gelling agent and an antifungal azole such as econazole; treating oral and vaginal fungal and bacterial infections
12/18/2003US20030232086 Gel composition for the topical treatment of rashes, dermatoses and lesions
12/18/2003US20030232083 Modified release dosage form
12/18/2003US20030232082 Modified release dosage forms
12/18/2003US20030232080 For enhancing dissolution and absorption of active ingredients
12/18/2003US20030232079 DPC 333 formulation having unique biopharmaceutical characteristics
12/18/2003US20030232078 Formulation & dosage form for the controlled delivery of therapeutic agents
12/18/2003US20030232077 Rapidly disintegrating tablet
12/18/2003US20030232074 For stimulating immune activation; for screening immunostimulatory compounds
12/18/2003US20030232073 Enhanced drug delivery in transdermal systems
12/18/2003US20030232072 Pharmaceutical composition and method for treating hypogonadism
12/18/2003US20030232070 Antifungal nail lacquer and method using same
12/18/2003US20030232067 Producing a blunted glycemic response in a diabetic patient by administering pullulan
12/18/2003US20030232065 Exposing an upper vertebra and a lower vertebra; identifying site for fusion between upper and lower vertebra; exposing bone surface on each of upper and lower vertebra at site for fusion; administering HMG-CoA reductase inhibitor to the site
12/18/2003US20030232064 For the introduction of anesthesia into an enclosed space for the purpose of rendering occupants of enclosed space unconscious
12/18/2003US20030232063 Aminosulfonic acid compounds for promoting desquamation of the skin
12/18/2003US20030232057 Method and composition for inducing tolerance to an antigenic material
12/18/2003US20030232053 Administering to treat rheumatoid arthritis, cancer, restenosis
12/18/2003US20030232024 For therapy of hyperpigmentation and vitiligo
12/18/2003DE10215316C1 Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer Quinoline and isoquinoline derivatives, to a pharmaceutical agent and their use as anti-inflammatory agents
12/18/2003CA2590618A1 Method of treating cancer using kinase inhibitors
12/18/2003CA2497609A1 Non-peptidic brs-3 agonists
12/18/2003CA2490037A1 Galactosyl isomalt, a method for producing it and its use
12/18/2003CA2489091A1 Inhibitors against activation of nf-kappab
12/18/2003CA2488979A1 Medicament for treatment of neurodegenerative diseases
12/18/2003CA2488974A1 Medicament for treatment of cancer
12/18/2003CA2488861A1 Use of orally-available prostacyclin derivatives for the production of a medicament for the treatment of disease states associated with bone marrow oedema
12/18/2003CA2488803A1 Use of ramoplanin to treat diseases associated with the use of antibiotics
12/18/2003CA2488801A1 Ether substituted imidazopyridines
12/18/2003CA2488798A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488760A1 N-benzoylureidocinnamate derivatives, method for production and use thereof
12/18/2003CA2488691A1 Extended release formulation of divalproex sodium
12/18/2003CA2488618A1 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
12/18/2003CA2488617A1 Nanoparticulate sterol formulations and sterol combinations
12/18/2003CA2488613A1 Novel formate salt of o-desmethyl-venlafaxine
12/18/2003CA2488609A1 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003CA2488602A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488567A1 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003CA2488498A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
12/18/2003CA2488493A1 Amidine derivatives for treating amyloidosis
12/18/2003CA2488402A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003CA2488385A1 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
12/18/2003CA2488367A1 Antiallergic agents
12/18/2003CA2488360A1 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
12/18/2003CA2488347A1 Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
12/18/2003CA2488342A1 Therapeutic drug for diabetes
12/18/2003CA2488249A1 Spliceosome mediated rna trans-splicing in stem cells
12/18/2003CA2488193A1 Inhibitors of the gpib -vwf interaction, their preparation and use
12/18/2003CA2488108A1 Liquid formulation of decitabine and use of the same
12/18/2003CA2487983A1 Method of treating cancer using kinase inhibitors
12/18/2003CA2487977A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003CA2487900A1 Immunity-related protein kinase inhibitors
12/18/2003CA2487899A1 Overactive bladder treating drug
12/18/2003CA2487891A1 Inhibitors against the activation of ap-1 and nfat
12/18/2003CA2487889A1 Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same
12/18/2003CA2487866A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
12/18/2003CA2487838A1 Methods and compounds for inhibiting the cytokine or biological activity of mif
12/18/2003CA2487428A1 Cd200-receptor mediated modulation of bone development
12/18/2003CA2487420A1 Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
12/18/2003CA2487147A1 Combinations comprising epothilones and pharmaceutical uses thereof
12/18/2003CA2486584A1 Compositions and methods for treating diabetes
12/18/2003CA2486581A1 Substituted phenylsulfonamide inhibitors of beta amyloid production
12/18/2003CA2486544A1 Use of an agent inducing dopachrome tautomerase (trp-2) expression as protecting agent for hair follicle melanocytes and uses thereof
12/18/2003CA2486491A1 4-(aryl or heteroaryl)-2-butylamine derivatives and their use as glucocorticoid ligans
12/18/2003CA2485725A1 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
12/18/2003CA2485709A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
12/18/2003CA2484514A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
12/18/2003CA2483555A1 Gamma lactams as prostaglandin agonists and use thereof
12/17/2003EP1371728A1 Gene encoding adseverin
12/17/2003EP1371666A2 Use of desulfated heparin
12/17/2003EP1371648A1 Phthalazine derivatives phosphodiesterase 4 inhibitors
12/17/2003EP1371647A2 Pyridine-3-carboxylic acid derivatives and their use as intermediates
12/17/2003EP1371646A1 Aryl-substituted alicyclic compound and medical composition comprising the same
12/17/2003EP1371645A1 Process for the preparation of the 2'-(R)-Glycopyrronium Enantiomers and their use in medicaments
12/17/2003EP1371640A1 Novel a-lipoic acid derivative and use thereof
12/17/2003EP1371376A1 Antipruritics
12/17/2003EP1371372A1 Use of active substance mixtures containing tocopherols and harpagophytum procumbens extracts for the preparation of a drug against rheumatic arthritis
12/17/2003EP1371371A1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for preventing and treating sexual disorder
12/17/2003EP1371370A1 Drugs containing reduced vitamin b2
12/17/2003EP1371369A1 Compositions comprising remifentanil
12/17/2003EP1371368A1 Salvianolic acid components as lipase inhibitors
12/17/2003EP1371367A1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
12/17/2003EP1371366A1 Methods for the prevention and/or the treatment of neurological disorders
12/17/2003EP1371362A1 Composition for treatment of inflammatory disorders
12/17/2003EP1371361A1 Novel suppository form comprising an acid-labile active compound
12/17/2003EP1371289A1 Choline-silicic acid complex
12/17/2003EP1370685A2 Diagnosis of diseases associated with dna repair
12/17/2003EP1370684A2 Polynucleotides related to colon cancer
12/17/2003EP1370673A1 Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
12/17/2003EP1370670A2 Processes for enhanced production of pantothenate
12/17/2003EP1370586A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370584A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370580A2 A new essential downstream component of the wingless signalling pathway
12/17/2003EP1370573A2 Low molecular serine protease inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
12/17/2003EP1370570A2 Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
12/17/2003EP1370569A1 Process for preparing n6-substituted aminopurine ribofuranose nucleosides
12/17/2003EP1370568A1 Chemical compounds
12/17/2003EP1370566A1 Synthetic derivatives of 21-butenyl and related spinosyns
1 ... 5240 5241 5242 5243 5244 5245 5246 5247 5248 5249 5250 5251 5252 5253 5254 5255 5256 5257 5258 5259 5260 ... 7860